Meeting Banner
Abstract #1260

Using Simultaneous PET/MRI and Cell Tracking to Evaluate Immunotherapies in Breast and Ovarian Cancer Models

Brianna Kelly1,2, Victoria Gonzalez1,2, Marie-Laurence Tremblay1, Andrea Nuschke1, Christa Davis1, Alecia MacKay3, Andrea West3, Barbara Vanderhyden4, Genevieve Weir3, Marianne Stanford2,3, and Kim Brewer1,2

1Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada, 2Dalhousie University, Halifax, NS, Canada, 3Immunovaccine Inc., Halifax, NS, Canada, 4Ottawa Hospital Research Institute, Ottawa, ON, Canada

Epithelial ovarian cancer and triple negative breast cancer (TNBC) are aggressive cancers with poor survival outcomes. Simultaneous FDG-PET/MRI and quantitative cell tracking were used to monitor orthotopic ovarian cancer and TNBC models for longitudinal tumor growth and metabolism in response to therapy while tracking immune cell subsets labeled with superparamagnetic iron oxide (SPIO). PET/MRI enabled monitoring of tumor growth and internal physiological changes and allowed quantitative assessment of tumor volumes over time. MRI cell tracking results indicated changes in the recruitment rates of three unique immune cell types over time in the group level with significant individual-level variability.

This abstract and the presentation materials are available to members only; a login is required.

Join Here